Throughout the last three months, 9 analysts have evaluated Definitive Healthcare DH, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 0 | 6 | 1 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 6 | 1 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Definitive Healthcare, presenting an average target of $5.61, a high estimate of $7.50, and a low estimate of $4.00. This current average represents a 24.6% decrease from the previous average price target of $7.44.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Definitive Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
David Larsen | BTIG | Announces | Buy | $7.00 | - |
George Hill | Deutsche Bank | Lowers | Hold | $5.00 | $7.00 |
Saket Kalia | Barclays | Lowers | Equal-Weight | $4.00 | $6.00 |
Vikram Kesavabhotla | Baird | Lowers | Neutral | $5.00 | $6.00 |
Craig Hettenbach | Morgan Stanley | Lowers | Equal-Weight | $5.00 | $9.00 |
David Grossman | Stifel | Lowers | Buy | $7.50 | $9.50 |
Saket Kalia | Barclays | Lowers | Equal-Weight | $6.00 | $7.00 |
Vikram Kesavabhotla | Baird | Lowers | Neutral | $6.00 | $8.00 |
Anne Samuel | JP Morgan | Lowers | Underweight | $5.00 | $7.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Definitive Healthcare. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Definitive Healthcare compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Definitive Healthcare's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Definitive Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Definitive Healthcare analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Definitive Healthcare
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
Definitive Healthcare: A Financial Overview
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Definitive Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 4.56%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Definitive Healthcare's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -335.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Definitive Healthcare's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -28.39%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.22%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.4, Definitive Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.